Marshall JK - Search Results

1

Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.

Fischer A, Mac S, Freiman ES, Marshall JK, Rand K, Ramos-Goñi JM. Fischer A, et al. Among authors: marshall jk. Pharmacoecon Open. 2025 Jan;9(1):41-56. doi: 10.1007/s41669-024-00523-5. Epub 2024 Oct 8. Pharmacoecon Open. 2025. PMID: 39377864 Free PMC article.

2

Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.

Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Marshall JK, et al. Pharmacoeconomics. 2001;19(10):1039-49. doi: 10.2165/00019053-200119100-00005. Pharmacoeconomics. 2001. PMID: 11735672

3

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.

Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Fenu E, et al. Among authors: marshall jk. Pharmacoecon Open. 2022 Jul;6(4):519-537. doi: 10.1007/s41669-022-00331-9. Epub 2022 Apr 26. Pharmacoecon Open. 2022. PMID: 35474178 Free PMC article.

4

Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.

Marshall JK, Irvine EJ. Marshall JK, et al. Aliment Pharmacol Ther. 1995 Jun;9(3):293-300. doi: 10.1111/j.1365-2036.1995.tb00384.x. Aliment Pharmacol Ther. 1995. PMID: 7654892 Clinical Trial.

5

Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.

Comay D, Blackhouse G, Goeree R, Armstrong D, Marshall JK. Comay D, et al. Among authors: marshall jk. Can J Gastroenterol. 2007 Apr;21(4):217-22. doi: 10.1155/2007/791062. Can J Gastroenterol. 2007. PMID: 17431509 Free PMC article.

6

Are there epidemiological differences between Crohn's disease and ulcerative colitis?

Marshall JK. Marshall JK. Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S1. doi: 10.1002/ibd.20578. Inflamm Bowel Dis. 2008. PMID: 18816716 No abstract available.

7

Patient outcomes after anti TNF-alpha drugs for Crohn's disease.

Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Assasi N, et al. Among authors: marshall jk. Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20384563 Review.

8

Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Marshall JK, et al. Cochrane Database Syst Rev. 2012 Nov 14;11:CD004118. doi: 10.1002/14651858.CD004118.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152224 Review.

9

Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?

Narula N, Fine M, Colombel JF, Marshall JK, Reinisch W. Narula N, et al. Among authors: marshall jk. Inflamm Bowel Dis. 2015 Jul;21(7):1683-94. doi: 10.1097/MIB.0000000000000350. Inflamm Bowel Dis. 2015. PMID: 25839775 Review.

10

Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.

Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Narula N, et al. Among authors: marshall jk. Am J Gastroenterol. 2016 Apr;111(4):477-91. doi: 10.1038/ajg.2016.7. Epub 2016 Feb 9. Am J Gastroenterol. 2016. PMID: 26856754 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters